NASDAQ:MGNXMacroGenics Stock Price, Forecast & News

MacroGenics' stock was trading at $6.49 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MGNX stock has increased by 237.3% and is now trading at $21.89. View which stocks have been most impacted by Coronavirus.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 1 sell rating and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for MacroGenics.

MacroGenics is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for MacroGenics.

MacroGenics Inc (NASDAQ:MGNX) posted its quarterly earnings results on Tuesday, May, 5th. The biopharmaceutical company reported ($0.91) earnings per share for the quarter, topping analysts' consensus estimates of ($1.01) by $0.10. The biopharmaceutical company earned $13.68 million during the quarter, compared to the consensus estimate of $7.43 million. MacroGenics had a negative return on equity of 62.43% and a negative net margin of 222.14%. View MacroGenics' earnings history.

13 analysts have issued 1 year price objectives for MacroGenics' shares. Their forecasts range from $6.00 to $50.00. On average, they anticipate MacroGenics' share price to reach $29.33 in the next twelve months. This suggests a possible upside of 34.0% from the stock's current price. View analysts' price targets for MacroGenics.

News articles about MGNX stock have been trending positive on Tuesday, according to InfoTrie. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. MacroGenics earned a media sentiment score of 2.6 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutMacroGenics.

MacroGenics saw a decline in short interest in May. As of May 15th, there was short interest totaling 2,860,000 shares, a decline of 11.2% from the April 30th total of 3,220,000 shares. Based on an average trading volume of 2,620,000 shares, the short-interest ratio is currently 1.1 days. Currently, 6.6% of the shares of the stock are sold short. View MacroGenics' Current Options Chain.

Some companies that are related to MacroGenics include ChemoCentryx (CCXI), Blueprint Medicines (BPMC), Agios Pharmaceuticals (AGIO), BridgeBio Pharma (BBIO), Deciphera Pharmaceuticals (DCPH), Arrowhead Pharmaceuticals (ARWR), Amicus Therapeutics (FOLD), PTC Therapeutics (PTCT), Allakos (ALLK), FibroGen (FGEN), HUTCHISON CHINA/S (HCM), Arena Pharmaceuticals (ARNA), Uniqure (QURE), Axsome Therapeutics (AXSM) and Insmed (INSM). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other MacroGenics investors own include AbbVie (ABBV), Exelixis (EXEL), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), NVIDIA (NVDA), Bausch Health Companies (BHC), Epizyme (EPZM), Incyte (INCY), Karyopharm Therapeutics (KPTI) and Nektar Therapeutics (NKTR).

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

MacroGenics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.72%), Invesco Ltd. (9.12%), Wasatch Advisors Inc. (5.32%), State Street Corp (3.90%), Rhenman & Partners Asset Management AB (2.04%) and Nuveen Asset Management LLC (1.81%). Company insiders that own MacroGenics stock include Eric Blasius Risser, Jeffrey Stuart Peters, Matthew K Fust and Thomas Spitznagel. View institutional ownership trends for MacroGenics.

MGNX stock was sold by a variety of institutional investors in the last quarter, including Pinnacle Associates Ltd., Rhenman & Partners Asset Management AB, Morgan Stanley, Spark Investment Management LLC, Principal Financial Group Inc., Two Sigma Investments LP, Deutsche Bank AG, and GSA Capital Partners LLP. Company insiders that have sold MacroGenics company stock in the last year include Eric Blasius Risser, and Thomas Spitznagel. View insider buying and selling activity for MacroGenics.

MGNX stock was bought by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Ikarian Capital LLC, Nuveen Asset Management LLC, Acadian Asset Management LLC, Russell Investments Group Ltd., Thrivent Financial for Lutherans, BlackRock Inc., and Geode Capital Management LLC. View insider buying and selling activity for MacroGenics.

Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MGNX stock can currently be purchased for approximately $21.89.

MacroGenics has a market capitalization of $1.08 billion and generates $64.19 million in revenue each year. The biopharmaceutical company earns $-151,810,000.00 in net income (profit) each year or ($3.16) on an earnings per share basis. MacroGenics employs 364 workers across the globe.

The official website for MacroGenics is www.macrogenics.com.

MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at 301-251-5172.